Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q)

German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q) and Its Potential Use in Large Cohorts

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The SCD-Q (Subjective Cognitive Decline-Questionnaire) is an established instrument to quantify self-perceived cognitive decline. Both self- and informant-rated versions of the SCD-Q are available. However, the SCD-Q has not been validated in the German language yet. Hence, the investigators aim to validate the self-reported SCD-Q in a clinical sample in Germany.

Who May Be Eligible (Plain English)

Who May Qualify: - Medical appointment for dementia diagnostics at the Alzheimer Therapie- und Forschungszentrum - Provision of signed, written and dated willing to sign a consent form - Capacity to give willing to sign a consent form Who Should NOT Join This Trial: - dementia in a very advance stage - Illiteracy Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Medical appointment for dementia diagnostics at the Alzheimer Therapie- und Forschungszentrum * Provision of signed, written and dated informed consent * Capacity to give informed consent Exclusion Criteria: * dementia in a very advance stage * Illiteracy

Treatments Being Tested

DIAGNOSTIC_TEST

Subjective Cognitive Decline-Questionnaire (SCD-Q)

The SCD-Q is an established instrument to quantify self-perceived cognitive decline. In addition to the self-perceived cognitive complaints, a 24 items questionnaire of informants is part of SCD-Q. The self-reported SCD-Q will be included in the standard health questionnaire that all patients of the memory clinic of the LMU Department of Psychiatry and Psychotherapy are required to complete before the examination date. The health questionnaire will be sent per mail. All routine clinical procedures will remain unchanged.

DIAGNOSTIC_TEST

Cognitive Failure Questionnaire (CFQ)

The Cognitive Failure Questionnaire (CFQ) is a questionnaire for measuring self-reported subjective failures in cognition, memory and motor functions in everyday life. The German CFQ consists of 32 items related to everyday possibilities of error, whose frequency in the last six months is to be estimated by means of a five-point rating scale.

DIAGNOSTIC_TEST

biomarkers

Blood plasma and serum samples will be collected by the project staff according to standard operating procedures used at LMU Munich and subsequently processed and measured at the Department of Psychiatry and Psychotherapy to quantify the blood-based biomarkers for AD using Elecsys immunoassays running on a Cobas e402 analyzer. Only available clinical and biomarker data will be used (Routine cerebrospinal fluid biomarkers, routine imaging biomarkers).

DIAGNOSTIC_TEST

Cognitive Tests

The investigators plan to examine the patients´ visuospatial performance on site with a digital clock-drawing test, which has been validated in large community-based studies. The Functional Activities Questionnaire (FAQ) shall be filled out by an informant. FAQ is a reliable and valid measure of activities of daily living. The results of the routine neuropsychological tests (Consortium to Establish a Registry for AD, Mini-Mental-State Examination) will be used in the analysis.

Locations (1)

Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums
München, Bavaria, Germany